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abstract: Objectives: This study aimed to describe the epidemiology of diabetes mellitus over the past two 
decades in Oman, particularly in terms of its prevalence and incidence. In addition, the study sought to estimate 
the future incidence of diabetes in Oman. Methods: Three national and three regional surveys conducted between 
1991 and 2010 were analysed to obtain the age-adjusted prevalence and undiagnosed proportion of type 2 diabetes 
mellitus (T2DM) among Omani subjects aged ≥20 years. Diabetes mellitus registers and published studies were 
used to determine incidence rates of both type 1 diabetes mellitus (T1DM) and T2DM in Oman. Linear regression 
was used to determine trends and projections for diabetes in 2050. Results: The age-adjusted prevalence of T2DM 
in Oman varied from 10.4% to 21.1%, while the highest prevalence of impaired fasting glucose was found in males 
(35.1%). In comparison to men, higher incidence rates of T2DM were found in women (2.7 cases compared to 2.3 
cases per 1,000 person-years, respectively). No significant trends were observed for the prevalence or incidence 
of T2DM in both genders. Undiagnosed T2DM was more common in men (range: 33–68%) than women (range: 
27–53%). The results of this study show that by 2050, there will be an estimated 350,000 people with T2DM living in 
Oman (a 174% increase compared to estimates for 2015). Conclusion: Health authorities need to prioritise diabetes 
prevention and control in order to prevent or delay long-term complications and avert a potential epidemic of 
diabetes in Oman.
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انت�ساره  املا�سيني يف عمان، وخا�سة من حيث  العقدين  مدى  على  ال�سكري  وبائيات  اإىل و�سف  الدرا�سة  هذه  تهدف  الهدف:  امللخ�ص: 
ووقوعه. كما �سعت الدرا�سة لتقدير معدالت وقوع ال�سكري يف امل�ستقبل يف �سلطنة عمان. الطريقة: جرى حتليل ثالثة م�سوح وطنية وثالثة 
م�سوح اإقليمية اأجريت بني عامي 1991م و 2010م للح�سول على معدل االنت�سار املعدل بح�سب العمر ون�سبة االأفراد غري امل�سخ�سني بالنوع 
الثاين من ال�سكري بني االأفراد الذين ترتاوح اأعمارهم 20 �سنة فاأكرث. وا�ستخدمت �سجالت ال�سكري والدرا�سات املن�سورة لتحديد معدالت 
االإ�سابة بالنوعني االأول والثاين. كما مت ا�ستخدام االنحدار اخلطي لتحديد االجتاهات والتوقعات لداء ال�سكري لعام 2050. النتائج: تراوح 
معدل االنت�سار املعدل بح�سب العمر للنوع الثاين من ال�سكري يف عمان من %10.4 اإىل %21.1، يف حني بلغت اأعلى ن�سبة انت�سار الختالل 
ال�سكر على الريق يف الذكور )%35.1(. وباملقارنة مع الرجال، وجد اأعلى معدل ارتفاع ملعدالت الوقوع للنوع الثاين من الداء ال�سكري يف 
الن�ساء )2.7 حالة مقارنة مع 2.3 حالة لكل 1,000 �سخ�ض-�سنة، على التوايل(. ومل ُيالحظ وجود اأي اجتاه معتد لالنت�سار اأو االإ�سابة للنوع 
الثاين من ال�سكري يف كال اجلن�سني. كانت ن�سبة النوع الثاين من ال�سكري غري امل�سخ�ض اأكرث �سيوعا يف الرجال )املجال: %68-33( منه يف 
الن�ساء )املجال: %53-27(. نتائج هذه الدرا�سة تظهر اأنه بحلول عام 2050، �سيكون هناك ما يقدر بنحو 350,000 �سخ�ض م�سابون بالنوع 
الثاين من ال�سكري يف عمان )زيادة بن�سبة %174 باملقارنة مع التقديرات لعام 2015(. اخلال�صة: حتتاج ال�سلطات ال�سحية و�سع خطط 
الوقاية من ال�سكري وال�سيطرة عليه كاأولوية من اأجل منع اأو تاأخري م�ساعفاته على املدى الطويل وجتنب انت�سار وباء حمتمل لل�سكري يف 
�سلطنة عمان.
مفتاح الكلمات: ال�سكري؛ علم االأوبئة؛ معدل الوقوع؛ معدل االنت�سار؛ االجتاهات؛ عمان.
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Advances in Knowledge
- The epidemiology of diabetes mellitus (DM) and related conditions in Oman over the past 20 years is described, utilising data from six 
surveys conducted between 1991 and 2010.
- The prevalence, incidence, proportion of undiagnosed cases and projections of the number of diabetes cases expected in Oman by the 
year 2050 using current trends are estimated for the first time.
Application to Patient Care
- With the recognition of the high prevalence and incidence of DM and associated risk factors in Oman, governmental and public health 
authorities are recommended to prioritise the control and prevention of this condition.
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The global prevalence of diabetesmellitus is on the rise and is projected to increase by 55% between 2013 and 2035.1 
Currently, four out of five people with diabetes live 
in low- or middle-income countries where resources 
are scarce.1 The prevalence of diabetes is projected 
to double in the Middle Eastern and North African 
(MENA) region; three countries in the MENA region 
are already ranked amongst the global top 10 in terms of 
diabetes prevalence.1 Between 1990 and 2010, diabetes 
mellitus was also recorded as the fifth leading cause of 
death among Arab states of the MENA region.2
Oman is classified as a high-income country and 
the total population is estimated to reach 3.6 million 
inhabitants, of which 58% are nationals.3,4 Nearly 14% 
of the population are under five years of age, 34% are 
under 15 years and only 6% are aged 60 years or over.5 
The World Health Organization (WHO) classifies 
Oman as a country with low child and adult mortality 
rates (crude death rate: 3.2 per 1,000).6 In terms of 
diabetes mellitus prevalence, Oman is ranked eighth 
among the top 10 countries of the MENA region.7 In 
2010, diabetes mellitus was the fourth leading cause 
of premature mortality in the country and the third 
leading cause of disability-adjusted life years lost.8 
In the early 1990s, the Omani Ministry of Health 
believed that non-communicable diseases, particularly 
type 2 diabetes mellitus (T2DM) and cardiovascular 
diseases (CVD), constituted a major and increasing 
workload for clinicians in Omani hospitals. A WHO 
ad hoc consultation found that 9% of all adult hospital 
admissions, 12% of all hospital bed occupancy and 20–
30% of all outpatient attendance in regional hospitals 
were associated with diabetes mellitus.9 
To the best of the authors’ knowledge, although 
several epidemiological studies of diabetes have been 
published in Oman, none have collated data over the 
past two decades in a comprehensive single study as 
of yet. The aim of this study was therefore to provide 
a summary and up-to-date data on the epidemiology 
of diabetes mellitus in Oman from the early 1990s to 
2010, as well as to estimate the future incidence of 
diabetes in Oman based on current trends.
Methods
Data from the following three national and three 
regional population-based surveys were analysed. 
The National Diabetes Survey was conducted in 1991 
to ascertain and validate the findings of the previous 
WHO ad hoc consultation.10 Thereafter, the National 
Health Survey in 2000 and the Oman World Health 
Survey in 2008 were conducted to monitor various 
health indicators, including changes in the prevalence 
of diabetes.11,12 In addition, the city of Nizwa (located 
150 km south of the capital city, Muscat) conducted 
two regional surveys, known as the Nizwa Healthy 
Lifestyle Project Surveys, in 2001 and 2010 to monitor 
CVD risk factors.13,14 A third regional survey, the 
Healthy Lifestyle Study, was conducted in 2006 in the 
city of Sur (located 200 km east of Muscat).15
Each national survey was designed to include 
a nationally representative sample and included all 
11 governorates of Oman. The regional surveys also 
followed a similar sampling method. The response 
rate for these surveys ranged from 75–93%. The two 
national surveys (2000 and 2008) and two of the 
regional surveys (2006 and 2010) obtained blood 
samples to measure fasting plasma glucose (FPG) 
from subjects after they had fasted overnight for at 
least eight hours. In the 1991 and 2001 surveys, an oral 
glucose tolerance test (OGTT) was used to measure 
plasma glucose two hours post 75 g oral glucose load, 
as recommended by the WHO.16 Further methodolo-
gical details of each survey are published elsewhere.10–15
Data analysis was limited to Omani nationals 
aged ≥20 years with complete data regarding the 
following variables: nationality; age; gender; fasting 
blood glucose levels; plasma glucose levels two hours 
post 75 g oral glucose load; an existing diabetes 
diagnosis from a physician, or a newly diagnosed 
case of diabetes. Patients were determined to have 
undiagnosed diabetes (UD) if they had stated that 
they were not diabetic but had a fasting blood glucose 
(FBG) level of ≥7 mmol/L. Proportions of UD cases 
were calculated by dividing the number of UD cases 
by the total number of subjects with a FPG level of 
≥7 mmol/L. Subjects who reported a diagnosis of 
diabetes from a health professional or who were taking 
anti-diabetic medications were classified to have 
T2DM regardless of their measured glucose levels. 
Glucose metabolism abnormalities, including diabetes 
mellitus, impaired glucose tolerance (IGT) and/
or impaired fasting glycaemia (IFG), were classified 
according to diagnostic criteria from both the WHO 
and the American Diabetes Association (ADA).16,17
Annual incidence rates for T2DM were calculated 
by dividing the number of all new cases diagnosed 
and documented in the National Diabetes Register in 
a calendar year by the estimated mid-year population 
at risk of that year to obtain cases per person-years 
(P-Y). The average incidence rate for the period 2003–
2013 was calculated by dividing the mean number 
of cases in this period by the mean P-Y at risk in the 
same period. As gender distribution of diabetes cases 
for the years 2003–2007 was not available, the mean 
gender distribution in subsequent years (2008–2012) 
was calculated and applied to that period. The mean 
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age at diagnosis for incidence cases was calculated 
from aggregated age groups by multiplying the mid-
interval of the age group by the frequency in that 
group. Population data and projections were obtained 
from the Annual Health Reports and the Directorate 
General of Planning of the Omani Ministry of Health.5
Trends over time were determined by gender 
for prevalence rates of T2DM and IFG using linear 
regression, with prevalence as a dependent variable 
and study year as an independent variable. A P value 
of <0.05 for the regression slope was considered 
to be significant. 
Age-standardised prevalence rates of T2DM 
were calculated using the world standard population 
determined by Segi.18 Linear regression was used 
to evaluate the gender-specific increase in T2DM 
prevalence per year. Projections of expected cases of 
T2DM between 2015 and 2050 were calculated by 
multiplying the gender-specific expected prevalence 
by the population.
Statistical analysis was performed using Stata® 
data analysis and statistical software, Version 11 
(StataCorp LP, College Station, Texas, USA).
Results 
Among subjects aged ≥20 years, the 1991 survey, which 
was the first epidemiological survey to map T2DM in 
Oman, found the crude prevalence of T2DM to be 
10.7% and the prevalence of IGT to be 10.3% [Table 1]. 
In the 2000 and 2008 surveys, the T2DM prevalence 
was 11.1% and 9.6%, respectively. A similar prevalence 
rate was found in the 2001 survey carried out in Nizwa 
(9.9%). The highest crude prevalence of T2DM was 
recorded in Sur in 2006 (13.9%), with 13.5% for males 
and 14.1% for females. 
Age-adjustment inflated all prevalence rates, 
particularly in the 2006 survey in Sur, where the 
highest T2DM rates were observed in females (21.1%). 
The prevalence of IFG varied drastically depending 
on the diagnostic criteria used. With WHO criteria, 
most IFG prevalence rates were between 5–7%, while 
age-adjusted rates were between 7–10% [Table 1]. On 
the other hand, using ADA criteria led to much higher 
prevalence rates of IFG (three to four times higher than 
the crude rates). The combined proportion of Omanis 
affected by either diabetes or IFG/IGT exceeded 30% 
in two of the regional studies in Nizwa and Sur (2001 
and 2006) [Figure 1]. Neither of the diagnostic criteria 
showed a statistically significant trend in crude or 
age-adjusted prevalence rates of T2DM and IFG for 
both genders [Figure 2]. The mean age of subjects with 
prevalent diabetes during successive surveys increased 
from 47.4 years in 1991 to 51.4 years in 2008 and 52.5 
years in 2010. 
It was found that there were approximately 4,900 
new cases of T2DM diagnosed in Oman each year 
among patients aged ≥20 years. The mean age of 
incident cases was 48 years, with males at 48.1 years 
and females at 47.8 years (P = 0.001; male to female 
ratio = 100:113). The incidence rate of T2DM in 
females was higher than males (2.7 compared to 2.3 
cases per 1,000 P-Y, respectively; P = 0.789). The age-
specific incidence rate increased in both genders from 
0.7 cases per 1,000 P-Y in the second decade, peaking 
in the fifth decade for both men and women (14 and 
16 cases per 1,000 P-Y, respectively) and declining 
thereafter. No significant temporal trend in incidence 
rate over two decades was observed for men or women 
(Ptrend = 0.42 and 0.43, respectively).
Table 2 shows that the proportion of subjects 
with UD decreased in Nizwa from 60.3% in 2001 
to 30.7% in 2010. Overall, men had a significantly 
higher proportion of UD (51.5%) compared to women 
(42.8%; P = 0.009).
Table 3 forecasts the total number of T2DM cases 
expected in Oman between 2015 and 2050 by gender, 
using mean prevalence rates of the national surveys 
and the predicted increase rate using linear regression 
models. On average, more than 350,000 people with 
T2DM are estimated to be living in Oman in 2050. 
This is an increase of approximately 174% compared 
to 2015.
Discussion
A persistently high prevalence of T2DM among sub- 
jects aged ≥20 years in Oman over the past two 
decades was found after analysing data from six 
surveys, reaching as high as 21% in the region of Sur. 
Similar rates have been reported in Egypt (15.2%), 
Saudi Arabia (16.2%), Qatar (16.7%) and Iran (9.3%).19 
A similar proportion of the Omani population suffer 
from IGT and/or IFG. Despite the statistically non-
significant increase in the trend of T2DM prevalence 
and incidence over the past two decades, the absolute 
number of people living with T2DM in Oman is 
expected to increase by 174% by the year 2050, when 
compared to current estimates. 
There are several indications of an impending 
epidemic of T2DM and CVD in Oman. First, high 
prevalences of obesity, physical inactivity and 
sedentary lifestyles have been reported in Oman.20 
Data regarding obesity from the three national surveys 
used in this study show an increasing proportion 
of males with a body mass index (BMI) of ≥30 kg/
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m2 (10.5%, 16.7% and 22.0% in 1991, 2000, and 2008 
surveys, respectively).10–12 While the prevalence of 
obesity among women remained stable between the 
1991 and 2000 surveys (25.1% and 23.8%, respectively), 
it increased in the 2008 survey to 26.0%.10–12 Despite 
this increase in the prevalence of obesity, the rate 
of diabetes has remained stable in Oman with no 
significant increase in trend among either gender. 
A similar analysis of data from the USA has shown 
doubling of both the incidence and prevalence of 
diabetes mellitus between 1990 to 2008; this increase 
subsequently plateaued between 2008 and 2012.21 The 
levelling off of both of these parameters is thought to 
be linked to the stabilisation of obesity rates in the 
Table 1: Crude and age-adjusted prevalence of diabetes mellitus, impaired glucose tolerance and fasting glycaemia 
among Omani adults aged ≥20 years between 1991–2010 according to diagnostic criteria




M F M F Total M F Total
DM by WHO criteria16
Ptrend - - 0.53 0.81 0.69 0.32 0.62 0.51
National (1991)10 Two hour post-OGTT 2,097 2,938 10.7 10.8 10.7 12.5 14.4 13.5
National (1991)10 FPG 2,097 2,938 10.2 8.8 9.4 11.6 11.5 11.5
National (2000)11 FPG 2,887 2,922 11.3 11.0 11.1 13.2 13.3 13.2
National (2008)12 FPG 1,259 1,479 10.6 8.8 9.6 13.0 11.5 12.2
Regional (Nizwa, 2001)13 Two hour post-OGTT 694 790 10.4 9.5 9.9 12.3 14.2 13.0
Regional (Nizwa, 2001)13 FPG 694 790 8.7 7.1 7.8 10.6 10.8 10.4
Regional (Nizwa, 2010)14 FPG 827 1,024 10.9 8.3 9.5 13.9 12.3 12.9
Regional (Sur, 2006)15 FPG 599 772 13.5 14.1 13.9 17.9 21.1 19.5
Impaired glucose tolerance and impaired fasting glycaemia by WHO criteria16
Ptrend - - 0.87 0.53 0.68 0.79 0.71 0.73
National (1991)10 Two hour post-OGTT 2,097 2,938 7.3* 12.5* 10.3* 8.2* 14.3* 11.6*
National (1991)10 FPG 2,097 2,938 5.3 5.1 5.2 5.9 6.4 6.2
National (2000)11 FPG 2,887 2,922 7.2 5.2 6.2 7.9 5.8 6.8
National (2008)12 FPG 1,259 1,479 4.8 4.4 4.6 5.5 4.8 5.1
Regional (Nizwa, 2001)13 Two hour post-OGTT 694 790 14.7* 16.0* 15.4* 15.4* 18.1* 16.7*
Regional (Nizwa, 2001)13 FPG 694 790 10.1 5.8 7.8 10.9 7.4 9.0
Regional (Nizwa, 2010)14 FPG 827 1,024 6.4 6.5 6.5 7.5 7.4 7.5
Regional (Sur, 2006)15 FPG 599 772 9.5 8.6 9.1 10.4 11.7 10.8
Impaired fasting glycaemia by ADA criteria17
Ptrend - - 0.68 0.52 0.58 0.66 0.59 0.61
National (1991)10 FPG 2,097 2,938 15.9 14.2 14.9 16.8 16.5 16.6
National (2000)11 FPG 2,887 2,922 18.3 14.0 16.1 19.5 15.0 17.3
National (2008)12 FPG 1,259 1,479 16.2 11.6 13.7 16.8 13.1 14.7
Regional (Nizwa, 2001)13 FPG 694 790 34.0 20.5 26.8 35.1 23.6 29.1
Regional (Nizwa, 2010)14 FPG 827 1,024 21.6 20.7 21.1 23.4 22.2 22.9
Regional (Sur, 2006)15 FPG 599 772 31.8 29.3 30.3 33.1 32.4 32.5
M = males; F = females; T = total; DM = diabetes mellitus; WHO = World Health Organization; OGTT = oral glucose tolerance test; FPG = fasting 
plasma glucose; ADA = American Diabetes Association. 
*Values for impaired glucose tolerance.
Epidemiology of Diabetes Mellitus in Oman 
Results from two decades of research 
e230 | SQU Medical Journal, May 2015, Volume 15, Issue 2
USA.21 Second, increasing urbanisation will lead to a 
future increase in diabetes; 75% of the current Omani 
population live in urban areas as compared to 47% in 
1980.22 Higher frequencies of T2DM and IGT were 
found in urban areas of Oman, such as Muscat (12% 
and 5.6%, respectively), compared to rural areas like 
the Musandam peninsula, which is over 400 km from 
Muscat (7.8% and 2.2%, respectively).23 
The third indicator of an impending epidemic of 
T2DM and CVD in Oman is the proportion of the 
population aged 65 years and over. This proportion is 
expected to increase 10 times by the year 2035 (from 
2.5% to 21%); this will also contribute to higher rates of 
diabetes.22 Finally, a high prevalence of IFG combined 
with a conversion rate of 5.6% per annum to diabetes 
and a high familial predisposition to diabetes is likely 
to aggravate the already high prevalence rates of 
this condition.24,25
In the present study, the incidence rate of T2DM 
among Omanis aged ≥20 years was 2.5 cases per 1,000 
P-Y. High incidence rates of T2DM have been reported 
from South Korea and Taiwan (7.6 and 7.7 per 1,000 
P-Y respectively),26,27 compared to Sweden (3.5 cases 
per 1,000 P-Y).28 
Changes in the diagnostic criteria for diabetes 
usually have an impact on diabetes incidence and 
prevalence depending on the cut-off values adopted. 
In 1997, the ADA adopted new diagnostic criteria for 
diabetes, followed by similar changes by the WHO 
in 1999.16,17 However, such changes did not affect 
the current study as original data collected from the 
field were analysed based on both WHO and ADA 
diagnostic criteria.
The only study documenting the incidence of 
childhood T1DM in children aged 0–14 years in Oman 
was conducted by Soliman et al. over two years.29 The 
reported incidence rate was 2.45 and 2.62 per 100,000 
P-Y in 1993 and 1994, respectively. The gender-specific 
incidence rates among boys and girls were 3.23 and 
1.99 per 100,000 P-Y in 1993 and 2.91 and 1.95 per 
100,000 P-Y in 1994, respectively. The age-specific 
incidence rates during these two years were higher 
 
Figure 1: Total age-adjusted prevalence of diabetes mellitus and impaired glucose tolerance/impaired fasting glucose 
among Omanis aged ≥20 years between 1991–2010 using data from six population-based national and regional 
surveys.10–15 The World Health Organization diagnostic criteria for diabetes was used.16 
IGT = impaired glucose tolerance; IFG = impaired fasting glycaemia; OGTT = oral glucose tolerance test; FPG = fasting plasma glucose.
 
Figure 2: Trend in age-adjusted prevalence of diabetes mellitus among Omani adults aged ≥20 years between 1991–2010 
using data from six population-based national and regional surveys.10–15 Trends are presented according to gender, survey 
and method of test used.
OGTT = oral glucose tolerance test; FPG = fasting plasma glucose.
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in the 10–14-year-old age group (3.69 and 4.22 per 
100,000 P-Y in 1993 and 1994, respectively) compared 
to those aged 5–9-year-old (2.32 and 2.79 per 100,000 
P-Y) and those aged 0–4-year-old (1.54 and 0.97 per 
100,000 P-Y). The same study also reported that the 
number of new cases was markedly higher in the 
relatively cooler months of the year (September to 
March).29 However, the reported incidence rate of 
T1DM in Omani children by Soliman et al. was lower 
than that reported in other Arabian Gulf states, such 
as Saudi Arabia and Kuwait (27.5 and 15.4 per 100,000 
P-Y, respectively).30,31
The present study observed that approximately 
30–60% of T2DM cases were undiagnosed in Oman. 
Similar or higher proportions have been reported 
from other Arab countries (75%, 48% and 62% in 
Tunisia, Saudi Arabia and Egypt, respectively).32 
Studies from developed nations such as France, 
Portugal and Finland have reported the prevalence of 
UD to be 50%, 44% and 61%, respectively.32 In an effort 
to detect UD cases earlier and to reduce the burden 
of diabetes and other non-communicable diseases 
in Oman, the Ministry of Health initiated a National 
Screening Programme in 2006 inviting subjects aged 
≥40 years to be screened for diabetes and other risk 
factors by attending their local primary healthcare 
centre after fasting overnight.33 Those who attended 
had their arterial blood pressure and weight measured 
and venous blood and urine samples collected. Results 
of the screening programme are shown in Table 4.33 
In 2007, Al-Lawati et al. developed a simple diabetes 
risk score to screen for T2DM among adults aged 
≥20 years.34 The tool contained specified scores for 
questions on age, waist circumference, BMI, family 
history of diabetes and current hypertension status. 
The sensitivity of the score was reported to be 78.6% 
and its specificity was 73.4%.34 The impact of both 
the screening programme and risk score have not yet 
been evaluated.
Current data from Omani Ministry of Health 
institutions indicate that 5% of all pregnant women are 
diagnosed with gestational diabetes mellitus (GDM).5 In 
addition, 14.3% of fetal deaths are attributed to diabetes 
during pregnancy.5 Dashora et al. reported testing 564 
women attending an antenatal clinic at a secondary hospital 
for glucose intolerance using an OGTT.35 Results indicated 
that 20.2% of women had two hour post-load glucose levels 
Table 2: Prevalence of undiagnosed diabetes mellitus 
among Omani adults aged ≥20 years between 1991–2010*
Survey type, location and year Prevalence of UD 
in %
M F T
National (1991)10 47.4 45.9 46.6
National (2000)11 64.0 53.4 58.7
National (2008)12 46.3 35.4 40.9
Regional (Nizwa, 2001)13 68.3 51.8 60.3
Regional (Nizwa, 2010)14 33.3 27.1 30.7
Regional (Sur, 2006)15 49.4 43.1 45.8
UD = undiagnosed diabetes mellitus; M = males; F = females; T = total. 
Table 3: Projected number of cases of diabetes among Omanis 
aged ≥20 years between 2015–2050*
Year Diabetes cases
M F T
2015 69,323 60,548 128,769
2020 80,490 69,779 149,195
2030 108,339 92,522 199,918
2040 149,571 125,425 274,265
2050 192,790 159,603 352,156
Total increase in % 178.1 163.6 173.5
M = males; F = females; T = total.
*Projections of expected cases were calculated by multiplying the gender-specific 
expected prevalence by the estimated population of that particular year .
Table 4: Prevalence of risk factors among Omanis aged ≥40 
years screened for selected non-communicable diseases in 
primary healthcare centres between 2008–2009*







Gender 38 62 100
BMI of ≥30 kg/m2 22 36 31
Abnormal WC** 54 76 68
Pre-HTN† 15 13 13
HTN‡ 22 19 20
Pre-diabetes§ 35 35 35
Diabetes¶ 10 7 8
High cholesterol 47 49 48
eGFR of <90 mL/
minute 
33 26 29
eGFR of <60 mL/
minute 
11 8 9
eGFR of <30 mL/
minute 
1 1 1
M = males; F = females; T = total; BMI = body mass index; WC = waist 
circumference; HTN = hypertension; eGFR = estimated glomerular filtration 
rate.
*Data from Oman Ministry of Health. Operational and Management 
Guidelines for the National Non-Communicable Diseases Screening Program. 
Muscat, Oman: Ministry of Health, 2009.33 **Defined as ≥94 cm for males and 
≥80 cm for females. †Defined as systolic blood pressure (SBP) of ≥130 mmHg 
and <140 mmHg and/or diastolic blood pressure (DBP) of ≥85 mmHg and <90 
mmHg. ‡Defined as SBP of ≥140 mmHg and/or DBP ≥ of 90 mmHg. §Defined 
as fasting plasma glucose (FPG) of ≥5.6 mmol/L and <7 mmol/L. ¶Defined as 
FPG of ≥7 mmol/L.
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of ≥7.8 mmol/L. Over 87% of cases of GDM in this 
study were diagnosed at the first antenatal visit (≤12 
gestational weeks). Second (at 16–20 gestational 
weeks) and third OGTT (at 24–28 gestational weeks) 
results added additional information in only a minority 
of cases (10% and 2.5%, respectively).35 In another 
study investigating GDM, Barakat et al. reported that 
women in Oman with GDM were three times more 
likely to have a child with macrosomia (adjusted odds 
ratio [OR] = 3.03) and to have a Caesarean section 
delivery (adjusted OR = 2.7).36 Adjusted ORs for the 
same conditions were 7.2 and 4.4 for women with pre-
gestational diabetes. 
The prevalence of GDM depends on the type 
of test and the diagnostic cut-off values used. In 
Oman, the reported prevalence of GDM (20.2%) 
was similar to that reported from the United Arab 
Emirates (20.6%) and Qatar (19.0%), but higher than 
that reported from Bahrain (13.5%) and Saudi Arabia 
(12.5%).35,37 However, Oman’s only study investigating 
GDM was based in a regional hospital.35 Thus, a 
national study to further elucidate the epidemiology 
of GDM may be warranted. With Oman being a 
high prevalence country, screening for GDM earlier 
than usually recommended (for example, at the first 
trimester rather than at 24–28 gestational weeks) may 
prove beneficial in the light of recent data which show 
that women with hyperglycaemia have an increased 
risk of adverse maternal, fetal and neonatal outcomes 
even within ranges of glycaemia previously considered 
normal for pregnant women.35,38 
Over the past four and a half decades, Oman 
has achieved conspicuous advances in the delivery 
of modern and free healthcare services to its entire 
population, including those living in remote areas. 
This has led to successful control and eradication of 
communicable diseases. On the other hand, the burden 
of non-communicable diseases, including diabetes, has 
increased.39 Despite this, information regarding how 
to prevent T2DM through lifestyle modifications is 
available.40 The public should be encouraged to adopt 
healthy lifestyles in order to prevent or delay T2DM 
and its complications. It is paramount that Omani 
health authorities pay greater attention to healthcare 
services that will result in reducing the burden of this 
condition in order to prevent or delay its complications 
and avert an impending epidemic.
The results of the current study highlight the 
current gaps in epidemiological knowledge and the 
need to update information regarding the incidence of 
T1DM. This may be done by investigating the accuracy 
of diabetes registers and examining ways to improve 
their utilisation in secondary and tertiary health 
institutions where the diagnosis of such cases occur. 
There is also a noticeable paucity of epidemiological 
data regarding the incidence and prevalence of T1DM 
in Oman, with the only available study dating back to 
two decades ago.29 As the incidence of this chronic 
disease is increasing worldwide, there is an urgent 
need to establish a national registry and to conduct 
further studies to monitor the magnitude of this 
condition to help plan for future healthcare services. 
Furthermore, no studies could be identified regarding 
the cost of diabetes in Oman. Thus, future work on 
determining the cost of diabetes to the Omani national 
health service would be vital.
The major strength of this study lies in the fact 
that all six surveys used for the data analysis were 
population-based with similar sampling methods 
and were thus representative and generalisable to 
the entire Omani population. However, the study has 
several limitations. First, in estimating the incidence 
of diabetes, an assumption of a full year of patient 
follow-up was made. This may have overestimated the 
incidence rate as some patients are censored during the 
study period (perhaps due to death, loss to follow-up, 
migration, etc.). Nonetheless, it is worthwhile noting 
that local health centre staff make enquiries regarding 
patients who do not follow-up their treatments and 
these patients are henceforth struck from the diabetes 
register which minimises this bias. Second, incidence 
rates are also likely to be underestimated as nearly 50% 
of diabetic subjects are undiagnosed; hence the true 
incidence is likely to be twice that reported. Third, 
incidence data on diabetes registers are not specifically 
collected to determine incidence rates. Their accuracy 
and completeness is often undetermined, especially in 
the absence of any evaluation of such registers. 
Conclusion
There is a high prevalence of T2DM and, to a lesser 
extent, incidence of T2DM. Additionally, high 
proportions of UD cases were recorded in Oman. 
Health authorities need to prioritise detection, control 
and treatment strategies for this condition so that a 
future overwhelming epidemic of diabetes mellitus 
is averted in Oman. This may include encouraging 
the general population to adopt healthy lifestyles 
in order to prevent or delay T2DM and its related 
complications.
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